ArriVent BioPharma, Inc. (AVBP)
| Market Cap | 912.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -81.05M |
| Shares Out | 33.70M |
| EPS (ttm) | -3.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 116,783 |
| Open | 27.12 |
| Previous Close | 27.39 |
| Day's Range | 26.61 - 27.77 |
| 52-Week Range | 14.35 - 36.37 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 38.00 (+40.38%) |
| Earnings Date | Mar 4, 2025 |
About AVBP
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal grow... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for AVBP stock is "Strong Buy." The 12-month stock price forecast is $38.0, which is an increase of 40.38% from the latest price.
News
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
NEWTOWN SQUARE, Pa. and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company dedicated to accelerating the global developm...
ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median durat...
Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma
HAYWARD, Calif.--(BUSINESS WIRE)-- #biotechnology--Aarvik Therapeutics is pleased to announce that ArriVent BioPharma, Inc. has exercised the option to exclusively license the collaboration program.
ArriVent BioPharma Reports Second Quarter 2024 Financial Results
Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation at t...
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
First-line monotherapy data for once daily firmonertinib selected as an oral presentation in the presidential session
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
Collaboration will leverage Alphamab's antibody drug conjugate (“ADC”) research and discovery platform and ArriVent's global development and commercialization expertise
ArriVent Appoints John Hohneker, M.D., to its Board of Directors
NEWTON SQUARE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, t...
ArriVent BioPharma Reports First Quarter 2024 Financial Results
NEWTOWN SQUARE, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of in...
ArriVent Appoints Kristine Peterson to its Board of Directors
NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics,...
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
BEIJING, China--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study...
ArriVent BioPharma Reports Full Year 2023 Financial Results
NEWTOWN SQUARE, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of ...
ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment
ArriVent raised $150 million in an upsized IPO, marking one of the strongest performances for a China-linked IPO in New York over the last two years. The company has licensed global rights, excluding ...